SOUTH SAN FRANCISCO, Calif., Feb. 25, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2015 financial results after close of market on Thursday, March 10, 2016. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and business progress.
The live webcast and subsequent replay of the earnings call may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Alternatively, please call (855) 541-0980 (U.S.) or (970) 315-0440 (international) to listen to the live conference call. The conference ID number is 49854042. The webcast replay will be available on the company's website approximately two hours following completion of the call and archived on the company's website for 90 days following the presentation.
In addition, Bonnie H. Anderson, president and chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9, 2016 at 10:40 a.m. Eastern Time.
The live audio webcast and subsequent replay of the conference presentation may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.
About Veracyte Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's Afirma® Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier (GEC) and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for nearly 175 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta® Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. Veracyte is developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.